Inspira Technologies signed a collaboration term sheet with the Beilinson Hospital in Israel for the evaluation of its proprietary INSPIRA ART100 device in organ transplant procedures. This Term Sheet marks a significant advancement and opportunity for the company in its technology being extended for use in additional medical segments and markets. The hospital shall provide Inspira with access to the internally logged data and diagnostics from the use of the Device and user feedback from medical doctors, certified clinical perfusionists, and other caregivers. The data is intended to be freely used by Inspira. Beilinson Hospital is an organ transplant center in Israel conducting over 70% of the organ transplants in Israel.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IINN:
- Inspira Announces Breakthrough Infection Prevention Tech
- Inspira and Ennocure reports results from infections prevention system
- Inspira Technologies Shareholders Approve Agenda
- Inspira Technologies Innovates Neonatal Respiratory Support
- Inspira Technologies begins program to explore use of Inspira device as womb